Malignant hyperthermia in India

Gupta, Pawan Kumar; Hopkins, Philip M.

doi:10.1111/j.1365-2044.2010.06532.x

Cited by 5 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar case reports were published by Gupta et al in 2010 and Pillai et al in 2015 wherein the patients couldn't be saved despite aggressive supportive measures. 7,8 Indian literature has examples of reported cases of malignant hyperthermia that survived this ordeal with early diagnosis and supportive management. In 2007 Saxena et al published a case of almost certain diagnosis of malignant hyperthermia with CGS of 61 where the patient survived and the triggering agents used were halothane and succinylcholine.…”

Section: Discussionmentioning

confidence: 99%

Successful management of malignant hyperthermia without dantrolene – A case report

Nara,

Yalla

2024

IJCA

View full text Add to dashboard Cite

Malignant hyperthermia (MH) is a rare inherited genetic disorder implicated in a life-threatening catastrophic event under general anaesthesia. In India, the total number of reported cases are of the magnitude of single digit due to lack of reporting. The mortality of MH is dramatically decreased from 70-80% to less than 5%, due to an introduction of dantrolene sodium for treatment of MH, early detection of MH episode using capnography, and the introduction of diagnostic testing for MH.In India, there is enormous dependence on clinical grading scale rather than halothane caffeine contraction test due to the lack of availability of accredited testing facilities. In addition to this, the drug of choice dantrolene, is not readily available everywhere in India. The scarcity of quintessential monitoring techniques cannot be ignored in peripheral areas. Despite these limitations many reported cases have survived with vigilant monitoring, prompt diagnosis and aggressive supportive care.

show abstract

Section: Discussionmentioning

confidence: 99%

Successful management of malignant hyperthermia without dantrolene – A case report

Nara,

Yalla

2024

IJCA

View full text Add to dashboard Cite

show abstract

“…The most confirmatory test for MH, caffeine halothane contracture testing [8] has to be done ideally after a period of 3 months of a hypermetabolic crisis to prevent false positive results [9]. Currently we do not have facility for such testing anywhere in India [10]. It is also necessary that the lab doing a CHCT should have a control with which the contraction has to be compared [11].…”

Section: Discussionmentioning

confidence: 99%

Malignant hyperthermia in India: Time for awakening, useful facts on Dantrolene

Pillai

Koshy

Balakrishnan

et al. 2015

Egyptian Journal of Anaesthesia

View full text Add to dashboard Cite

A 33 year old lady with no obvious reason to suspect susceptibility to malignant hyperpyrexia (MH) succumbed to this unexpected complication in spite of attempts to save her life with aggressive supportive measures. We are reporting this case of possible malignant hyperthermia probably the seventh reported case in India and second from Kerala in the last decade (Saxena and Dua, 2007;Punj et al., 2001;Gopalakrishnan et al., 2010;Jain, 2010;Ramakant and Singh, 2012;Sharma et al., 2012). This was the first ever case of MH in our institution in 25 years This emphasises the need to ensure availability of Dantrolene and MH kits, diagnostic centres with appropriate lab controls and above all high index of suspicion and heightened awareness among the anaesthesiologists of this potential albeit rare risk of MH in Indian population.

show abstract